See Which Of The Latest 13F Filers Holds CVS

Aggregate 13F data through the 12/31/2025 filings show hedge funds increased their CVS holdings by 8,570,715 shares (from 268,351,485 to 276,922,200), a roughly 3.19% rise across 4,456 funds; in the reviewed batch of 31 filers, 9 held CVS with an aggregate change of -101,981 shares. Among all filers Vanguard Group (120,709,530), Geode Capital (29,040,271) and Pzena (15,581,307) were the largest holders, while individual fund moves in the sample included three increases, four decreases and two new positions. The report notes 13F limitations (no short positions disclosed), making the data most useful for monitoring positioning and flow rather than signaling definitive bullish conviction.

Analysis

Market structure: The 12/31/2025 13F batch shows modest institutional demand for CVS (aggregate +8.57M shares, +3.19% among funds), a demand shock large enough to nudge float dynamics but too small to change control. Direct beneficiaries are CVS (CVS) and its PBM/health-services peers (Caremark margin optionality); losers are pure retail rivals (WBA, RAD) if capital rotates into integrated healthcare models. The flow should modestly compress CVS equity implied volatility and, if persistent, tighten credit spreads by 10–30bp for CVS corporates in the next 1–3 months.

Risk assessment: Key tail risks are regulatory PBM reforms (CMS/FTC action) that could shave >5% off EBITDA, adverse Medicaid/Medicare reimbursement changes, or a surprising legal loss; these are low-probability but high-impact over 3–12 months. Short-term (days–weeks) price moves will track macro and quant rebalancing; medium-term (quarters) depends on PBM contract renewals and same-store pharmacy trends; long-term (years) hinges on care-delivery execution and leverage. Hidden dependency: 13Fs omit shorts—some reported buys may be hedge components of net-neutral trades, so interpret buy volume as directional only if corroborated by options/CDS flows.

Trade implications: Tactical long exposure to CVS favored on pullbacks: buy on >5% intraday weakness with a 6–12 month target of +15–25% if PBM margins stabilize; use 6–9 month call spreads to cap downside. Pair trade: long CVS vs short WBA (dollar-neutral) to capture PBM/vertical-integration premium. Avoid large outright positions before the next CMS/earnings windows (30–90 days).

Contrarian angles: The consensus buy is likely underweighting regulatory risk but may also be underestimating real-estate and care-delivery optionality that can re-rate CVS if management executes (think +10–20% rerating scenario over 12 months). Historical parallel: prior PBM regulatory scares compressed multiples then rebounded when fundamentals held; if short-interest is elevated, a stable earnings print could trigger squeeze. Unintended consequence: crowded hedged positions could amplify headline-driven volatility—prefer structured, capped-loss trades.

Key Decisions for Investors

• Establish a 1–2% long position in CVS on a pullback of ≥5% within the next 4 weeks; set a hard stop at 8% below entry and a 6–12 month target of +15–25% if PBM margins meet or beat consensus.
• Implement a dollar-neutral pair: long CVS (1.0% portfolio) and short WBA (0.75%) within 2 weeks to play PBM/integrated-care outperformance; unwind if relative moves exceed +15% favorable or -10% adverse.
• Buy 6–9 month call spreads on CVS to express upside with defined risk (limit premium to ≤1% of portfolio); alternatively, sell put spreads keyed to a 5–8% lower strike if willing to acquire stock, max loss defined.
• Monitor regulatory catalysts: if CMS/FTC issues PBM pricing proposals or guidance within 30–60 days that imply >5% EBITDA hit to consensus, reduce CVS exposure by 50% immediately; if no adverse action in 90 days and earnings reaffirm PBM guidance, add back exposure to 2–3%.